Some industry-funded clinical trials show signs of being designed to market drugs rather than to test them for their safety and effectiveness. Detecting these studies remains difficult.
Articles on Big Pharma
Displaying 1 - 20 of 119 articles
Some drugmakers have signalled their frustration with the UK’s approach – but it’s good for patients.
By extending their monopoly on a drug, companies prevent generics and other competitors from driving down prices. But increasing transparency can help prevent Big Pharma from gaming the patent system.
Pharmaceutical companies have little incentive to sell drugs to countries that can’t afford them. But bargaining together can increase access to vital treatments worldwide.
Big Tech and Big Pharma are complaining about Australian laws – and it could lead to more tariffs.
Patient advocacy groups are often funded through pharmaceutical companies, but there are currently no regulations governing disclosure of this potential conflict of interest.
Research found Big Pharma companies with global reach more likely to abide by environmental standards.
We suspect these drug company payments are just the tip of the iceberg.
Ozempic generated A$21 billion of sales in 2023 alone. So how was it developed? And how are its new competitors, Mounjaro and Zepbound, different?
Canada has a lack of transparency about Big Pharma’s payments to health-care providers and organizations. Disclosure is voluntary, and there’s no central data on even the few companies that do report.
A new study has found no evidence that people’s beliefs in conspiracy theories increase over time. They can even change their minds – just not that often.
Drug development takes a great deal of time, money and effort. While future profits play a big factor in which diseases gets prioritized, advocacy and research incentives can also tilt the scale.
Pharmaceutical and insurance industries that could lose profit through lower drug prices are not happy that a pharmacare bill is planned for fall. They are speaking out and mobilizing their allies.
Canadians pay very high drug costs, but Canada also does not receive the same economic benefits from pharmaceutical industry investments as other countries do.
The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
An anthropology course explores how peoples and cultures around the world use nature-based medicines to heal.
Health Canada continues to monitor newly approved drugs to determine if the benefits identified in the pre-market trials hold up to further scrutiny. Canadians need better access to that information.
Some commercial products and practices are directly linked to avoidable ill health, planetary damage, and social and health inequity. Large transnational corporations are especially to blame.
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
The Medicines Patent Pool was created to promote public health, facilitating generic licensing for patented drugs that treat diseases predominantly affecting low- and middle-income countries.
Top contributors
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Senior Research Manager, University of Sydney and Honorary Assistant Professor, Bond University
-
Professor of Bioethics, Macquarie University
-
Associate Professor, School of Law, University of Canberra
-
Professor of Bioethics & Medicine, Sydney Health Ethics, Haematologist/BMT Physician, Royal North Shore Hospital and Director, Praxis Australia, University of Sydney
-
Assistant Professor of Resource Economics, UMass Amherst
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Macquarie University Research Fellow, Macquarie University
-
Professor of Medicine and Public Health, University of Colorado Anschutz
-
Adjunct associate, Lancaster University
-
Associate Professor Politics and Policy Studies, Deakin University
-
Health activist, Medreach Pty Ltd., Bond University
-
Research Fellow, Asia Pacific Social Impact Centre, The University of Melbourne
-
Professor of Accounting, Durham University
-
Associate professor, School of Biomedical Sciences, University of Leeds